INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection

Bibliography

• PATTI JM, ALLEN BL, McGAVIN MJ, HOOK M: MSCRAMM-mediated adherence of microorganisms to host tissues. Ann. Rev. Microbiol. (1994) 48:585-617.
   PubMed Web of Science ®Google Scholar
• HOOK M, PATTI JM, McGAVIN M et al.: MSCRAMMs – Microbial Recognition Systems for Extracellular Matrix Molecules. In: Molecular Pathogenesis of Surgical Infections, Wadström T (Ed.), Gustav Fischer Verlag, Stuttgart, Germany (1994):137-44.
   Google Scholar
• MARTIN JA, HAMILTON BE, VENTURA SJ, MENACKER F, PARK MM: Births: final data for 2000. Natl. Vital. Stat. Rep. (2002) 50(5):1-101.
   Google Scholar
• FANAROFF AA, KORONES SB, WRIGHT LL et al.: Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr. Infect. Dis. J. (1998) 17(7):593-598.
   PubMed Web of Science ®Google Scholar
• ETZIONI A, OBEDEANU N, BLAZER S, BENDERLY A, MERZBACH D: Effect of an intravenous γglobulin preparation on the opsonophagocytic activity of preterm serum against coagulase-negative staphylococci. Acta Paediatr. Scand. (1990) 79(2):156-161.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, TANIUCHI S, HATTORI K, KOBAYASHI T, KINOSHITA Y, KOBAYASHI Y: Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates. Clin. Exp. Immunol. (1997) 107(3):435-439.
   PubMed Web of Science ®Google Scholar
• STOLL BJ, HANSEN N, FANAROFF AA et al.: Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 110(2 Part 1):285-291.
   PubMed Web of Science ®Google Scholar
• STOLL BJ, GORDON T, KORONES SB et al.: Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J. Pediatr. (1996) 129:63-71.
   PubMed Web of Science ®Google Scholar
• STOLL BJ, HANSEN NI, ADAMS-CHAPMAN I et al.: Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. J. Am. Med. Assoc. (2004) 292(19):2357-2365.
   PubMed Web of Science ®Google Scholar
• CDC: Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
   PubMedGoogle Scholar
• GARRETT DO, JOCHIMSEN E, MURFITT K et al.: The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Control. Hosp. Epidemiol. (1999) 20(3):167-170.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN RD, HARDMAN T, THORNTON J, HILL HR: A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates. J. Perinatol. (1989) 9:126 -130.
   PubMedGoogle Scholar
• BAKER CJ, MELISH ME, HALL RT, CASTRO DT, VASAN U, GIVNER LB: Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates. N. Engl. J. Med. (1992) 327(4):213-219.
   PubMed Web of Science ®Google Scholar
• FANAROFF AA, KORONES SB, WRIGHT LL et al.: A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N. Engl. J. Med. (1994) 330(16):1107-1113.
   PubMed Web of Science ®Google Scholar
• JENSEN HB, POLLOCK BH: Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics (1997) 99:E2.
   Google Scholar
• LACY JB, OHLSSON A: Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: metaanalyses. Arch. Dis. Child. Fetal. Neonatal Ed. (1995) 72:F151-F155.
   PubMed Web of Science ®Google Scholar
• OHLSSON A, LACY JB: Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst. Rev. (2004) 1:CD000361.
   PubMedGoogle Scholar
• Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis: the PREVENT Study Group. Pediatrics (1997) 99:93-99.
   PubMed Web of Science ®Google Scholar
• BLOOM BT, KUESER TJ, OELBERG DG et al.: A Phase I, multicenter study of safety and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Pediatric Academic Societies Annual Meeting, Seattle, USA (2003) (Abstract 1804).
   Google Scholar
• INHIBITEX, INC.: Investigator’s Brochure, INH-A21®, Version 4 (April 29 2005).
   Google Scholar
• VERNACHIO JH, BAYER AS, AMES B et al.: Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. (2006) 50:511-518.
   PubMed Web of Science ®Google Scholar
• CAPPARELLI EV, BLOOM BT, KUESER TJ et al.: Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor selected human staphylococcal immune globulin in low-birth-weight infants. Antimicrob. Agents Chemother. (2005) 49(10):4121-4127.
   PubMed Web of Science ®Google Scholar
• BLOOM B, SCHELONKA R, KUESER T et al.: Multicenter study to assess safety and efficacy of INH-A21, a donor selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low-birth-weight infants. Pediatr. Infect. Dis. J. (2005) 24(10):858-866.
   PubMed Web of Science ®Google Scholar
• WALSON PD: Patient recruitment: US perspective. Pediatrics (1999) 104(3 Part 2):619-622.
   PubMed Web of Science ®Google Scholar